Greywolf Therapeutics, Ltd.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

UK- and Australian-based Grey Wolf Therapeutics, Ltd. ’s lead clinical development candidate, GRWD5769, a selective oral ERAP1 inhibitor, has shown the potential to elicit a “powerful and differentia

Two new venture capital funds based outside of the US together offer $365m for life science start-ups, including Amplitude Ventures’ second fund and XGEN Venture’s inaugural fund. Montreal-based Ampli

The partners at Andera Life Sciences have been reflecting on a busy week which saw the France-headquartered private equity firm wave goodbye to portfolio company Amolyt Pharma , sold to AstraZeneca